Intellectus Partners, LLC Corvus Pharmaceuticals, Inc. Transaction History

Intellectus Partners, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 08, 2019	SELL	$3.3 - $4.58 $8,910 - $12,366	-2,700 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.75 - $4.97 $1,875 - $2,485	500 Added 22.73%	2,700 $11,000
Q4 2018 Feb 14, 2019	SELL	$3.29 - $8.94 $822 - $2,235	-250 Reduced 10.2%	2,200 $8,000
Q4 2017 Feb 13, 2018	BUY	$9.3 - $16.93 $21,948 - $39,954	2,360 Added 2622.22%	2,450 $25,000
Q3 2017 Nov 14, 2017	SELL	$11.3 - $17.23 $15,729 - $23,984	-1,392 Reduced 93.93%	90 $1,000
Q2 2017 Aug 15, 2017	BUY	N/A	1,482	1,482 $18,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Intellectus Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Intellectus Partners, LLC with notifications on news.